Kardigan Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Kardigan Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KARD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002123613
- EIN
- 93-2994203
Board of directors
-
Anastasios Gianakakos · Director · President & CEOSince 2026
-
David P. Meeker · DirectorSince 2026
-
Douglas E. Giordano · DirectorSince 2026
- Since 2026
-
Keith Crandell · DirectorSince 2026
-
Kimberly J. Popovits · DirectorSince 2026
-
Kristin Marie K. Reinke · DirectorSince 2026
- Since 2026
-
Paul L. Berns · DirectorSince 2026
- Since 2026
-
Steven Gillis · DirectorSince 2026
- Since 2026
Chief executives
Anastasios Gianakakos
· President & CEO
Since June 2026
Board connections
9 of this board's directors also sit on 33 other boards. 29 are in the same sector.
-
Neumora Therapeutics Inc. Same sectorvia Kristina Burow and Paul L. Berns
-
Rhythm Pharmaceuticals Inc. Same sectorvia David P. Meeker and Kimberly J. Popovits
- via Kimberly J. Popovits
- via Keith Crandell
-
Adagio Medical Holdings Inc Same sectorvia Joseph Edelman
-
Beam Therapeutics Inc. Same sectorvia Kristina Burow
-
BioMarin Pharmaceutical Inc. Same sectorvia Timothy P. Walbert
-
Boundless Bio Inc. Same sectorvia Kristina Burow
-
Century Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
City Therapeutics Inc. Same sectorvia Robert Nelsen
-
Freenome Inc. Same sectorvia Joseph Edelman
-
Gossamer Bio Inc. Same sectorvia Kristina Burow
-
Immatics N.V. Same sectorvia Joseph Edelman
-
Kiniksa Pharmaceuticals International plc Same sectorvia Kimberly J. Popovits
-
Latigo Biotherapeutics Inc. Same sectorvia Timothy P. Walbert
-
LeonaBio Inc. Same sectorvia Joseph Edelman
-
Lyell Immunopharma Inc. Same sectorvia Robert Nelsen
-
MeiraGTx Holdings plc Same sectorvia Joseph Edelman
-
Mirum Pharmaceuticals Inc. Same sectorvia Timothy P. Walbert
- via Joseph Edelman
-
Odyssey Therapeutics Inc. Same sectorvia Timothy P. Walbert
-
Pharvaris N.V. Same sectorvia David P. Meeker
-
Prime Medicine Inc. Same sectorvia Robert Nelsen
-
Q32 Bio Inc. Same sectorvia Steven Gillis
- via Keith Crandell
-
Sagimet Biosciences Inc. Same sectorvia Timothy P. Walbert
-
Sana Biotechnology Inc. Same sectorvia Robert Nelsen
-
Scholar Rock Holding Corporation Same sectorvia Kristina Burow
-
Solid Biosciences Inc. Same sectorvia Joseph Edelman
-
Takeda Pharmaceutical Company Limited Same sectorvia Steven Gillis
-
Trevi Therapeutics Inc. Same sectorvia David P. Meeker
-
Twist Bioscience Corporation Same sectorvia Keith Crandell
-
Vir Biotechnology Inc. Same sectorvia Robert Nelsen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $90,000,000
- 3 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 22, 2026 | HRTG PV, L.P. 10% owner | Open-market purchase | +3,125,000 | $16.00 | $50,000,000 |
| Jun 22, 2026 | Paul L. Berns Director, 10% owner | Open-market purchase | +1,250,000 | $16.00 | $20,000,000 |
| Jun 22, 2026 | Robert Nelsen Director, 10% owner | Open-market purchase | +1,250,000 | $16.00 | $20,000,000 |
| Jun 17, 2026 | Johnson Keith Bryon 10% owner | Derivative conversion | +2,050,166 | — | — |
| Jun 17, 2026 | ARCH Venture Partners XIII, LLC Director, 10% owner | Derivative conversion | +13,792,035 | — | — |
| Jun 17, 2026 | Andy Pasternak Officer (Chief Strategy Officer) | Grant or award | +79,640 | — | — |
| Jun 17, 2026 | David P. Meeker Director | Grant or award | +20,706 | — | — |
| Jun 17, 2026 | Paul L. Berns Director, 10% owner | Derivative conversion | +13,792,035 | — | — |
| Jun 17, 2026 | Moriarty John B Officer (Chief Legal Officer) | Grant or award | +47,784 | — | — |
| Jun 17, 2026 | Jahn Brianne Officer (Chief Financial Officer) | Grant or award | +79,640 | — | — |
| Jun 17, 2026 | Kimberly J. Popovits Director | Grant or award | +20,706 | — | — |
| Jun 17, 2026 | Timothy P. Walbert Director | Grant or award | +20,706 | — | — |
| Jun 17, 2026 | Anastasios Gianakakos Director, Officer (President & CEO) | Derivative conversion | +28,702 | — | — |
| Jun 17, 2026 | Douglas E. Giordano Director | Grant or award | +20,706 | — | — |
| Jun 17, 2026 | Edelberg Jay Officer (Chief Medical Officer) | Derivative conversion | +97,587 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Kardigan Inc.
Who is the CEO of Kardigan Inc.?
Anastasios Gianakakos has been Kardigan Inc.'s President & CEO since June 2026.
How many directors are on Kardigan Inc.'s board?
Kardigan Inc.'s board has 12 directors: Anastasios Gianakakos, David P. Meeker, Douglas E. Giordano, Joseph Edelman, Keith Crandell, Kimberly J. Popovits, Kristin Marie K. Reinke, Kristina Burow, Paul L. Berns, Robert Nelsen and 2 others.
Are Kardigan Inc. insiders buying or selling shares?
Over the last 12 months, Kardigan Inc. insiders bought $90.0 million of shares in 3 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="kardigan-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.